

# MicroRNA Levels as Prognostic Markers for the Differentiation Potential of Human Mesenchymal Stromal Cell Donors

## Citation for published version (APA):

Georgi, N., Taipaleenmaki, H., Raiss, C. C., Groen, N., Portalska, K. J., van Blitterswijk, C., de Boer, J., Post, J. N., van Wijnen, A. J., & Karperien, M. (2015). MicroRNA Levels as Prognostic Markers for the Differentiation Potential of Human Mesenchymal Stromal Cell Donors. *Stem Cells and Development*, 24(16), 1946-1955. <https://doi.org/10.1089/scd.2014.0534>

## Document status and date:

Published: 15/08/2015

## DOI:

[10.1089/scd.2014.0534](https://doi.org/10.1089/scd.2014.0534)

## Document Version:

Publisher's PDF, also known as Version of record

## Document license:

Taverne

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

# MicroRNA Levels as Prognostic Markers for the Differentiation Potential of Human Mesenchymal Stromal Cell Donors

Nicole Georgi,<sup>1</sup> Hanna Taipaleenmaki,<sup>2</sup> Christian C. Raiss,<sup>3</sup> Nathalie Groen,<sup>4</sup>  
Karolina Janaeczek Portalska,<sup>4</sup> Clemens van Blitterswijk,<sup>4</sup> Jan de Boer,<sup>4</sup>  
Janine N. Post,<sup>1</sup> Andre J. van Wijnen,<sup>5</sup> and Marcel Karperien<sup>1</sup>

The ability of human mesenchymal stromal/stem cells (hMSCs) to differentiate into various mesenchymal cell lineages makes them a promising cell source for the use in tissue repair strategies. Since the differentiation potential of hMSCs differs between donors, it is necessary to establish biomarkers for the identification of donors with high differentiation potential. In this study, we show that microRNA (miRNA) expression levels are effective for distinguishing donors with high differentiation potential from low differentiation potential. Twenty hMSC donors were initially tested for marker expression and differentiation potential. In particular, the chondrogenic differentiation potential was evaluated on the basis of histological matrix formation, mRNA expression levels of chondrogenic marker genes, and quantitative glycosaminoglycan deposition. Three donors out of twenty were identified as donors with high chondrogenic potential, whereas nine showed moderate and eight showed low chondrogenic potential. Expression profiles of miRNAs involved in chondrogenesis and cartilage homeostasis were used for the distinction between high-performance hMSCs and low-performance hMSCs. Global mRNA expression profiles of the donors before the onset of chondrogenic differentiation revealed minor differences in gene expression between low and high chondrogenic performers. However, analysis of miRNA expression during a 7-day differentiation period identified *miR-210* and *miR-630* as positive regulators of chondrogenesis. In contrast, *miR-181* and *miR-34a*, which are negative regulators of chondrogenesis, were upregulated during differentiation in low-performing donors. In conclusion, profiling of hMSC donors for a specific panel of miRNAs may have a prognostic value for selecting donors with high differentiation potential to improve hMSC-based strategies for tissue regeneration.

## Introduction

HUMAN MESENCHYMAL STROMAL/stem cells (hMSCs) are a multipotent cell source that can be easily harvested from various locations of the body, including bone marrow, periosteum, synovium, synovial fluid, adipose tissue, buccal fat pad, infrapatellar fat pad, and osteoarthritic cartilage [1–6]. The ability of hMSCs to differentiate into mesenchymal tissues, such as the bone and cartilage, and their potential as trophic mediators render them particularly suitable for tissue engineering [7].

Unfortunately, large interdonor variation of the differentiation potential is a general complication for the practical

implementation of hMSC-based tissue engineering approaches [8,9]. Donor age, method or location of harvest, culture conditions, and culture time are known to affect the differentiation potential of hMSCs [10–16]. Jansen et al. suggested that distinctions in mRNA gene expression profiles might be predictive for the differentiation potential [17]. However, specific biomarkers indicative for the differentiation potential of undifferentiated hMSCs remain to be defined.

Studies on the genetic and epigenetic mechanisms that control the differentiation potential of hMSCs have focused on characterizing variation in both mRNA and miRNA

<sup>1</sup>Department of Developmental BioEngineering, Faculty of Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the Netherlands.

<sup>2</sup>Heisenberg-Group for Molecular Skeletal Biology, Department of Trauma-, Hand- and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

<sup>3</sup>Nanobiophysics Group, Faculty of Science and Technology, MESA+ Institute for Nanotechnology, University of Twente, Enschede, the Netherlands.

<sup>4</sup>Department of Tissue Regeneration, Faculty of Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the Netherlands.

<sup>5</sup>Departments of Orthopedic Surgery and Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota.

expression levels [18–21]. MicroRNAs (miRNAs) control cell fate by negatively regulating protein accumulation through effects on the stability and/or translation of mRNAs for transcription factors and their phenotypic target genes. Hence, miRNAs are very relevant molecular candidates for mapping the proliferation and differentiation potential of hMSCs.

In this study, we tested a series of bone marrow-derived hMSCs from a cohort of donors for their potential to undergo chondrogenesis. This cohort has previously been characterized in great detail with respect to the osteogenic, adipogenic, endothelial cell differentiation potential and CD marker expression [22,23] and meets the criteria proposed by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy [24]. Similar to differentiation into other cell types, the chondrogenic potential varied significantly between donors.

The biological properties of these hMSCs were correlated with global mRNA expression profiles using microarray assays and quantitative polymerase chain reaction (qPCR) expression analysis of a select panel of miRNAs. To permit identification of miRNAs with a predictive value for chondrogenic differentiation, we examined miRNA expression both before the onset of differentiation and after the induction of chondrogenic differentiation at day 7 in pellet culture. We found that miRNA profiling of hMSC donors and patients may have a prognostic value in regenerative medicine by permitting identification of hMSCs that are most effective in supporting differentiation.

## Materials and Methods

### Cell expansion and differentiation

The use of human bone marrow aspirates was approved by the local medical ethics committee with written informed consent by the donors [25]. Aspirates were retrieved during total hip replacement surgery from the acetabulum or iliac crest (average age: 52 years, 25% male and 75% female). Aspirates were resuspended using a 20G needle and plated at a density of 0.5 million mononucleated cells/cm<sup>2</sup>. MSCs were selected by plastic adherence in proliferation media [alpha modified minimum essential medium, 10% fetal bovine serum (Lonza), 0.2 mM ascorbic acid, 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and 1 ng/mL of basic fibroblast growth factor (Instruchemie)]. hMSCs were expanded up to passage 2 and used in passage 3 to test their differentiation potential. The determination of cell surface marker expression (CD105, CD11b, CD19, CD45, HLA-DR, CD90, CD73, CD34), osteogenic potential, adipogenic potential, and endothelial induction of the used hMSC donors is described elsewhere [22,23].

### Chondrogenic differentiation

To induce chondrogenic differentiation, 250,000 hMSCs were seeded in round-bottom 96-well plates [26] at passage 2. Pellets were formed by centrifugation (500 rcf, 5 min) and maintained in chondrogenic differentiation media. This medium consists of Dulbecco's Modified Eagle's Medium supplemented with 40 mg/mL of proline, 50 mg/mL ITS-premix, 50 mg/mL of ascorbic acid, 100 mg/mL of sodium pyruvate, 100 U penicillin/mL, 100 mg/mL streptomycin, 10 ng/mL of transforming growth factor- $\beta$ , and 10<sup>-7</sup> M of

dexamethasone. Cells were cultured for 4 weeks for determination of glycosaminoglycan (GAG) deposition (quantitative and qualitative) and qPCR of chondrogenic markers and 1 week for the qPCR analysis of chondrogenesis-related miRNAs, as previously described [26]. Media were changed twice a week.

### Histology: Alcian Blue staining

After 4 weeks, chondrogenic culture pellets were fixed with 10% buffered formalin for 15 min, dehydrated, and embedded in paraffin using routine procedures. Sections of 5  $\mu$ m were cut and stained for sulfated GAGs with Alcian Blue (0.5%, in H<sub>2</sub>O, pH=1 adjusted with HCl, 30 min) combined with counterstaining of Nuclear Fast Red (0.1% in 5% aluminum sulfate, 5 min). Scoring of histology was performed by three independent blinded observers according to the intensity of Alcian Blue staining and morphology of the formed pellets.

### mRNA isolation and qPCR

After 4 weeks of chondrogenic culture, total RNA was isolated from pellet cultures with the NucleoSpin RNA II Kit (Bioke) and 1  $\mu$ g of RNA was reverse-transcribed into cDNA using the iScript cDNA Synthesis Kit (Bio-Rad) according to the manufacturer's protocols. The primers for qPCR are listed in Table 1. mRNA expression levels were normalized with GAPDH and B2M as housekeeping genes.

All reagents were purchased from Invitrogen, unless otherwise stated. Common chemicals were purchased from Sigma-Aldrich.

### Microarray expression profiling

Gene expression profiling of 20 hMSC donors was carried out using the Affymetrix microarray platform. RNA isolated at passage 2 before the initiation of the chondrogenic differentiation was hybridized to the Human Genome U133A 2.0 Array (Affymetrix) and scanned with a GeneChip G3000 scanner (Affymetrix). Measurements were normalized for

TABLE 1. PRIMERS USED FOR QUANTITATIVE POLYMERASE CHAIN REACTION

Gene symbol	Primer sequence	Length of amplicon (bp)
ACAN	5' AGGCAGCGTGATCCTTACC 3' 5' GGCCTCTCCAGTCTCATTTCTC 3'	136
COL1A1	5' GTCACCCACCGACCAAGAAACC 3' 5' AAGTCCAGGCTGTCCAGGGATG 3'	121
COL2A1	5' CGTCCAGATGACCTTCTTACG 3' 5' TGAGCAGGGCCTTCTTGTAG 3'	122
COL10A1	5' GCAACTAAGGGCCTCAATGG 3' 5' CTCAGGCATGACTGCTTGTAC 3'	129
SOX9	5' TGGGCAAGCTCTGGAGACTTC 3' 5' ATCCGGGTGGTCTTCTTGTG 3'	98
FRZB	5' ACGGGACACTGTCAACCTCT 3' 5' CGAGTCGATCCTTCCACTTC 3'	155
GAPDH	5' CGCTCTCTGCTCCTCTGTT 3' 5' CCATGGTGTCTGACCGATGT 3'	101
B2M	5' GACTTGTCTTTCAGCAAGGA 3' 5' ACAAAGTCACATGGTTTACA 3'	106

technical effects related to efficiency of hybridization and amplification of nucleic acids, as well as the physical location on the array. Data processing and statistical testing were performed using R and Bioconductor statistical software (www.bioconductor.org). Analysis to determine differential gene expression was performed using a linear modeling approach with empirical Bayesian methods, as implemented in the Limma package [27] and described in more detail in Mentink et al. [22]. Raw and normalized data have been deposited in the Gene Expression Omnibus database (http://ncbi.nlm.nih.gov/geo/, GSE39540). Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) was used to investigate the predicted gene–gene interaction network [28,29]. Clusters were formed using Markov clustering algorithms. Changes in upstream regulators and biofunctions were visualized using Ingenuity Pathway Analysis software (IPA<sup>®</sup>; Ingenuity Systems).

In this study, the described data set was previously used by Portalska et al. and Mentink et al. [22,23]. We reanalyzed this data set after the formation of two groups: good and low chondrogenic performing hMSC donors. To correlate donor variation with chondrogenic differentiation ability, we scored different donor-derived hMSCs based on their histological pellet culture appearance, GAG deposition, and expression of mRNA markers of chondrogenesis after 28 days of differentiation. Subsequently, a list of genes ranked on fold change between the highest and lowest chondrogenically performing donors was generated using the approach described above.

#### miRNA isolation and qPCR

Small RNAs were isolated from monolayer hMSC cultures at passage 2 and from pellet cultures at day 7 after initiation of chondrogenic differentiation with the AllPrep DNA/RNA/Protein Mini Kit in combination with the RNeasy<sup>®</sup> MinElute<sup>®</sup> Cleanup Kit according to the manufacturer's protocol (Qiagen). Nucleic acid concentrations were measured with the NanoDrop 2000. The small RNA fraction cDNA was prepared using the RevertAid H Minus First Strand cDNA Synthesis Kit (Fermentas). SYBR (*N'*,*N'*-

dimethyl-*N*-[4-[(*E*)-(3-methyl-1,3-benzothiazol-2-ylidene)methyl]-1-phenylquinolin-1-ium-2-yl]-*N*-propylpropane-1,3-diamine) green mRNA Primer sequences are listed in Table 2. The QuantiMir RT Kit (Systems Biosciences) was used according to the manufacturer's instruction to convert small RNAs into cDNA. Expression levels were analyzed by quantitative reverse transcription–polymerase chain reaction (qRT-PCR; SYBR Green supermix and iCycler IQ detection system; Bio-Rad) using conventional protocols [30]. The relative expressions were calculated by the  $\Delta$ CT method normalized to U6 expression.

The qRT-PCR data were analyzed using one-way analysis of variance with Tukey as the post hoc test (different sized groups) in SPSS. Significance levels of  $P \leq 0.05$  are indicated with an asterisk (\*).

## Results

### Limited chondrogenic potential of hMSC donors

hMSCs from a cohort of 20 donors were tested previously for their endothelial, adipogenic, osteogenic, and chondrogenic differentiation potential. All donor hMSCs expressed the anticipated CD marker profile of hMSCs [22,23]. We compared the chondrogenic potential in depth based on histological appearance, GAG deposition, and chondrogenic mRNA expression. This analysis revealed that only three donors show substantial chondrogenesis after 28 days of pellet culture. Another nine donors show moderate levels of chondrogenesis and eight donors have only a low potential to undergo chondrogenesis (Supplementary Fig. S1; Supplementary Data are available online at www.liebertpub.com/scd). Alcian Blue stain for the GAG of two representative donors of each group revealed that intensity of staining is decreasing from donors with high chondrogenic potential to donors with low chondrogenic potential. Reduction in GAGs is paralleled by limited abundance of encapsulated chondrocyte units (ie, reduced chondron formation), increased fibrous cartilage formation, and a higher cell to matrix ratio (Fig. 1A).


Gene expression levels of the chondrogenic genes *ACAN* and *COL2A1* were significantly upregulated in donors with high chondrogenic potential. The chondrogenic transcription factors *SOX9* and *FRZB*, a recently identified marker for articular cartilage, were nonsignificantly higher expressed in good chondrogenic performers. *COL10A1*, a marker for cartilage hypertrophy, was significantly higher expressed in high-performing donors. *COL1A1*, a dedifferentiation marker, exhibits limited variation in expression between the different groups (Fig. 1B). Donors with high chondrogenic potential show distinct quantitative GAG levels from moderate to low performers (Fig. 1C). Histologically assessed GAG levels did not distinguish moderate from low-performing donors (Fig. 1C). Thus, high-performing chondrogenic hMSCs are distinct from biologically low-performing hMSCs by both histochemical and molecular criteria.

### Microarray-based mRNA expression profiling shows limited distinctions between hMSCs with different chondrogenic potential

Analysis of global gene expression levels between all 20 donors revealed minor mRNA expression differences between the high-, moderate-, and low-performing donors. To improve

TABLE 2. PRIMERS USED FOR THE QUANTITATIVE POLYMERASE CHAIN REACTION OF MICRORNA

MicroRNA	Primer sequence
Universal reverse primer	5'-GACGAGGACTCGAGCTCAAGCT-3'
Oligo-dT-adaptor	5'-GACGAGGACTCGAGCTCAAGCTTT TTTTTTTTTTTTTT-3'
U6	5'-CGCAAGGATGACACGCAAATTC-3'
Mir-30b	5'-TGTAACATCCTACACTCAGCT-3'
Mir-221	5'-AGCTACATTGTCTGCTGGGTTTC-3'
Mir-34a	5'-TGGCAGTGTCTTAGCTGGTTGT-3'
Mir-23b	5'-TGGGTTCTGGCATGCTGATTT-3'
Mir-26	5'-TTCAAGTAATCCAGGATAGGCT-3'
Mir-181	5'-AACATTCAACGCTGTCGGTGAG-3'
Mir-210	5'-CTGTGCGTGTGACAGCGGCTGA-3'
Mir-630	5'-AGTATTCTGTACCAGGGAAGGT-3'
Mir-140	5'-TACCACAGGGTAGAACACGG-3'
Mir-145	5'-GTCCAGTTTTCCAGGAATCCCT-3'
Let-7e	5'-TGAGGTAGGAGGTGTATAGTT-3'



**FIG. 1.** Comparison of 20 human mesenchymal stromal/stem cell (MSC) donors for their chondrogenic potential based on histological appearance, mRNA expression, and glycosaminoglycan (GAG) deposition. (A) Alcian Blue stain for GAG of two representative donors of each group: high chondrogenic potential (a, b) to donors with moderate (c, d) and low chondrogenic potential (e, f). (B) Gene expression levels of the chondrogenic genes *ACAN*, *COL2A1*, and *COL10A1* were assessed with quantitative polymerase chain reaction analysis using mRNAs. Data represent the three donors in the high-performing group, nine donors in the moderate group, and eight donors in the low-performing group  $\pm$  standard deviation (SD) ( $*P \leq 0.05$ ). (C) GAG levels as overview for all 20 donors: donors with high chondrogenic potential demonstrate distinct quantitative GAG levels compared to moderate and low performers. The average measure of three different pellets per donor  $\pm$  SD is illustrated. Color images available online at [www.liebertpub.com/scd](http://www.liebertpub.com/scd)


detection of molecular differences, we compared mRNA levels upon biological stratification of the donors into two groups with either high or low chondrogenic potential ( $n=3$  in each case) using the extremes at both ends of the spectrum of chondrogenic differentiation based on histology, quantitative GAG assessment, and gene expression analysis. Statistical evaluation of these highly distinct groups increased the number of significantly differentially expressed genes, but differences in global gene expression levels were small (Supplementary Table S1).

STRING network analysis of genes with a minimal 1.6-fold (log ratio 0.5) upregulation in donors with high chondrogenic potential compared to low-performing donors demonstrated changes in regulatory networks associated with transcriptional control and signal transduction. One major network includes the basic helix-loop-helix family member E40 (BHLHE40), which is a transcription factor modulating chondrogenesis [31]. Furthermore, several other gene regulatory factors were identified, such as the nuclear receptor group 4A2 (NR4A2, also known as NURR1) as well as the basic leucine zipper

(bZIP) proteins *ATF3*, *MAFB*, *FOSB*, and *FOS*. Each of these regulators has been linked to signal transduction, cell proliferation, and differentiation [32] (Fig. 2A).

Network analysis of genes with a minimal 1.4-fold downregulation in donors with low chondrogenic potential compared to donors with high chondrogenic potential revealed major networks associated with extracellular matrix proteins, such as *ACAN*, *COL4A1*, *TIMP3*, and *EFEMP1*, as well as a network of signaling proteins, *JAG1*, dickkopf-related protein 1 (*DKK1*), and tumor necrosis factor receptor superfamily member 11B (*TNFRSF11B*, also known as osteoprotegerin/OPG) (Fig. 2B).

Ingenuity pathway analysis revealed that the 10 most differentially regulated cellular functions between the three high- and low-performing donors were linked to development as well as cell growth and survival (Fig. 2C). Transforming growth factor (TGF)- $\beta$ 1 was identified as a major upstream contributor to the differences in gene expression between donors with high and low chondrogenic potential (Fig. 2D).



**FIG. 2.** Microarray mRNA analysis as a result of the comparison of three high-performing chondrogenic donors versus low-performing chondrogenic donors. **(A)** Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) network analysis of genes with a minimal 1.4-fold upregulation in donors with high chondrogenic potential compared to inefficient performing donors. **(B)** STRING network analysis of genes with a minimal 1.4-fold downregulation in donors with low chondrogenic potential compared to donors with high chondrogenic potential. The number of connecting lines indicates the reported evidence of connection between displayed proteins. **(C)** Ingenuity pathway analysis of the top 10 differentially regulated cellular functions between the three high- and low-performing donors. **(D)** Transforming growth factor- $\beta$ 1 was identified as a major upstream contributor to the differentially regulated genes between donors with high and low chondrogenic potential. Color images available online at [www.liebertpub.com/scd](http://www.liebertpub.com/scd)

### Differential expression of miRNAs between groups with distinct chondrogenic potential

Since mRNA expression changes did not reveal clear markers of chondrogenic potential, we investigated the potential of miRNA expression as markers of chondrogenic potential in hMSCs. The expression of previously identified miRNAs known to be involved in chondrogenesis was evaluated before onset of chondrogenic differentiation and after 7 days in a three-dimensional cell mass under chondrogenic conditions (pellet culture). miRNA levels of the same three donors with high chondrogenic potential ( $n=3$ ) were compared with the same three donors with lowest chondrogenic potential ( $n=3$ ).


Two miRNAs, which are known to negatively influence osteoblast and chondrocyte differentiation (*miR-30b* and *-221*), display a higher expression in high-performing donors before the onset of chondrogenesis (fold upregulation high-performing donor/low-performing donor: *miR-30b*: 1.63, *miR-221*: 1.83). Both miRNAs were strongly downregulated during chondrogenic differentiation (fold downregulation day 0/day 7: *miR-30b*: 4.10, *miR-221*: 7.86). However, these same miRNAs were not or weakly downregulated in low-performing chondrogenic donors, marked by a lower fold change between day 0 and 7 after induction of chondrogenic differentiation (fold downregulation day 0/day 7: *miR-30b*: 0.94, *miR-221*: 2.72).

One set of miRNAs (*miR-34a*, *-23b*, *-26*, *-181*) was more highly expressed in donors with high chondrogenic potential before the onset of chondrogenesis (fold difference between high- vs. low-performing donors: *miR-34a*: 2.46-fold, *miR-23b*: 1.25-fold, *miR-26*: 1.54-fold, *miR-181*: 1.15-fold). These miRNAs were all downregulated during differentiation (fold downregulation day 0/day 7: *miR-34a*: 3.70-fold, *miR-23b*: 1.67-fold, *miR-26*: 1.20-fold, *miR-181*: 1.10-fold). Remarkably, while their expression in poor performing donors was lower compared to good performing donors before the onset of chondrogenic differentiation, their expression was upregulated during differentiation (fold upregulation day 0/day 7: *miR-34a*: 1.90-fold, *miR-23b*: 1.30-fold, *miR-26*: 1.60-fold, *miR-181*: 1.39-fold). Notably, *miR-34a* and *miR-23b* are known to negatively influence cartilage homeostasis and/or chondrogenic differentiation.

In contrast, expression of *miR-630*, a positive regulator of chondrogenesis, and *miR-210*, a marker of the hypoxic cell response, is upregulated during chondrogenesis (fold upregulation day 0/day 7: good donors *miR-630*: 1.99, *miR-210*: 14.14; low donors: *miR-630*: 3.52, *miR-210*: 21.93). Remarkably, their upregulation was even more pronounced in the poor performing donors, demonstrating discordance. Other regulators of chondrogenesis (*miR-140*, *-145*, and *let-7e*) display only minor differences between the different groups (Fig. 3; Table 3).

## Discussion

By the comparison of the chondrogenic differentiation potential of previously well-characterized hMSCs from a cohort of human donors ( $n=20$ ), it was shown that only 15% of these donors provide hMSCs with the natural capability to undergo efficient chondrogenic differentiation *in vivo* [22,23], while chondrogenic performance was moder-



**FIG. 3.** MicroRNA (miRNA) level regulation of high-performing vs low-performing donors. Expression of miRNAs known to be involved in chondrogenesis was evaluated before chondrogenesis and at day 7 of chondrogenic pellet culture. miRNA levels of donors with high chondrogenic potential ( $n=3$ ) were compared with donors with low chondrogenic potential ( $n=3$ ). *miR-30*, *-221*, *34a*, *-23b*, *-26*, *-181* display a higher expression in high-performing donors before the onset of chondrogenesis and were strongly downregulated during chondrogenic differentiation. *miR-630* and *miR-210* are upregulated during chondrogenesis. Negative regulators of chondrogenesis (*miR-145* and *let-7e*) are slightly downregulated during the differentiation process in high- and low-performing donors. Data represent the mean of three independent hMSC donors. Color images available online at [www.liebertpub.com/scd](http://www.liebertpub.com/scd)

ate (45%) or even poor in the remaining donors (40%). Good chondrogenic differentiation potential was mainly marked by increased GAG deposition, better histological cartilage formation, including increased formation of matrix encapsulated chondrocytes (ie, chondron formation), limited fibrous cartilage formation, as well as the significantly higher mRNA expression of *ACAN* and *COL2A1*.

The main focus of our study was, therefore, to define molecular differences that predict high differentiation hMSC donors at the start of the differentiation experiment. We would like to emphasize that this pool of MSCs was isolated from bone marrow biopsies by virtue of plastic adherence using protocols routinely applied for isolation and culture expansion of bone marrow MSCs for clinical practice [33]. Our MSCs were not clonally selected and they are likely to present a heterogenic cell population as previously noted [24].

Previous studies have mainly focused on the osteogenic differentiation of hMSC donors. In these studies, only differences in differentiation potential were noticed and no scoring was done. Differences in performances were shown to be independent of donor age, gender, and source of isolation [9,22,34]. As demonstrated by Mentink et al. [22], high osteogenic potential of a particular donor does not imply that this donor also exhibits high chondrogenic, adipogenic, or endothelial differentiation potential. We, therefore, want to emphasize that prognostic markers have to be identified for each differentiation lineage separately.

In our study, we tested if donors with high chondrogenic potential could be identified in a pool of donors based on their global gene expression profile determined by Affymetrix

TABLE 3. INVESTIGATED MICRORNAs AND THEIR REPORTED FUNCTION

miRNA	Reported function	References	Observed regulation
miR-30b	Negative regulation of osteoblast differentiation	[48]	Higher expressed in high performers at day 0
miR-221	Negative regulation of chondrocyte differentiation	[49,50]	Higher expressed in high performers at day 0; downregulated during differentiation in high performers; no regulation in low performers
miR-34a	Regulates osteoarthritis pathogenesis	[46]	Higher expressed in high performers at day 0; upregulation in low performers during chondrogenesis
miR-23b	Potentially upregulated in osteoarthritis (OA); negative regulation of TGF $\beta$ and BMP signaling	[51,52]	Higher in high performers at day 0; upregulation in low performers during chondrogenesis
miR-26	Mediates cholesterol metabolism; hypoxic upregulation	[53,54]	Higher expressed in high performers at day 0; upregulation in low performers during chondrogenesis
miR-181	Regulation of TGF $\beta$ signaling in chondrocytes; downregulation during chondrogenesis; hypoxic upregulation	[43,54,55]	Higher expressed in high performers at day 0; upregulation in low performers during chondrogenesis
miR-210	Upregulation during chondrogenesis cell survival of MSC hypoxic upregulation	[20,50,54]	Upregulation in both donor groups during chondrogenesis
miR-630	Activation of TGF $\beta$ signaling in chondrocytes	[43]	Upregulation during differentiation; higher upregulation in good responders
miR-140	Positive regulation of chondrogenesis; negative regulation of histone deacetylase 4 (HDAC4); regulation of OA pathogenesis; and endochondral bone formation	[40–42]	Higher expressed in high performers; decreased during chondrogenesis
miR-145	Negatively regulates chondrogenesis by targeting SOX9; downregulation during chondrogenesis	[50,55,56]	Higher expressed in high performers; decreased during chondrogenesis
Let-7e	Downregulation during chondrogenesis self-renewal of stem cells	[50,57]	Higher expressed in low performers; downregulation during chondrogenesis

TGF $\beta$ , transforming growth factor-beta; MSC, mesenchymal stromal/stem cell; BMP, bone morphogenetic protein.

microarray analysis before the onset of differentiation. Groups with high and low chondrogenic differentiation potential were separated with a maximum 1.6-log ratio in transcript expression levels (Supplementary Table S1).

Donors with low chondrogenic potential mainly exhibited higher expression of matrix-associated proteins. Donors with high chondrogenic potential showed increased expression of mRNAs involved in transcriptional processes, although overall differences were small. Two regulatory networks that differ between the donor groups with high and low chondrogenic potential are centered around the BHLHE40, as a transcriptional factor modulating chondrogenesis [31], and the transcription factors FOS, FOSB, and ATF3, which have general roles in signal transduction, cell proliferation, and differentiation [35] (Fig. 2A). FOS and ATF members are leucine zipper proteins that dimerize with the JUN family and, thereby, form a large number of AP-1-related transcription factor complexes. The activation of AP-1 is linked to terminal chondrocyte differentiation and cartilage homeostasis by modulating MMP13 expression [36]. Modulation of this transcription factor network may therefore have impact on the chondrogenic performance of hMSCs. Hence, subtle differences in the expression of transcription factors may contribute to distinctions in the chondrogenic potential of hMSCs.

Our studies suggested that genes, which differ between donors with high or low chondrogenic potential, are linked to TGF $\beta$ 1 as a principal upstream regulator. TGF $\beta$  signaling supports embryonic development and cartilaginous matrix formation [37]. It is plausible that differences in TGF $\beta$

responsiveness of hMSC donors might lead to distinct chondrogenic performance of hMSCs. Indeed, exogenous supplementation of TGF $\beta$  is a main driver of chondrogenic differentiation in hMSC pellet cultures [38]. In addition, TGF $\beta$  is a key upstream regulator of AP-1 activity through its downstream effectors SMAD2 and SMAD3 [39]. Thus, differences in the TGF $\beta$ /SMAD/AP1 regulatory axis could account, in part, for differences in the chondrogenic ability of hMSCs from different donors.

We next extended our analysis by analysis of a selected panel of miRNAs previously implemented in chondrogenic differentiation, including *miR-210*, *miR-630*, and *miR-140* [40–43]. We confirmed positive regulation of *miR-210* and *miR-630* within 7 days after chondrogenic induction, with *miR-630* being slightly higher expressed in good donors. Bakhshandeh et al. showed that *miR-630* is part of a chondrogenic miRNA signature [43]. Among the pathways predicted to be targeted by *miR-630* are erbB signaling, gap-junction communication, MAP-Kinase signaling, and TGF $\beta$  signaling. Both MAP-Kinase/Erk signaling and TGF $\beta$  signaling are mediators of early stages of chondrogenic differentiation [44,45].

We find that *miR-181* and *miR-34a*, which are negative regulators of chondrogenesis, were upregulated during differentiation in low-performing donors. Of these two, *miR-34a* perturbs cartilage homeostasis by inducing apoptosis, cell cycle arrest, and senescence while targeting for E2F3, cyclin E2, CDK6, and others [46,47], but is otherwise unremarkable. However, similar to one of the predicted functions for *miR-*

630, *miR-181* acts as a negative regulator of the TGF $\beta$  pathway [43]. Thus, our current findings converge on a hypothetical molecular model, in which *miR-630*, *miR-181*, as well as the TGF $\beta$ /SMAD/AP-1 regulatory axis may form a tightly connected network that modulates and predicts the chondrogenic potential of hMSCs from different donors.

In conclusion, our findings indicate that a panel of miRNAs encompassing *miR-210*, *miR-630*, *miR-181*, and *miR-34a* can be informative for prognostically separating high-performing hMSCs from low-performing hMSCs. Our data suggest that a short preclinical differentiation period of 7 days suffices to provide insight into the chondrogenic potential of different hMSCs based on miRNA expression profiling. Furthermore, modulation of TGF $\beta$  responsiveness appears to be a common mechanistic denominator in both the observed differences in mRNA expression profiles and the differences in miRNA expression between biologically distinct hMSCs from different donors. We anticipate that experimental and therapeutic manipulation of TGF $\beta$ -dependent miRNA/transcription factor networks may be useful for enhancing the chondrogenic potential of hMSCs and minimizing the biological differences among diverse patients who will undergo autologous tissue regeneration using hMSCs.

### Acknowledgments

The authors gratefully acknowledge the support of the TeRM Smart Mix Program of the Netherlands Ministry of Economic Affairs and the Netherlands Ministry of Education, Culture and Science, the support of National Institutes of Health grant R01 AR049069 (to A.J.v.W.) as well as the EMBO and the Alexander von Humboldt Foundation support (post-doctoral fellowships H.T.). M.K. is supported by a long-standing program grant of the Dutch Arthritis Association.

### Author Disclosure Statement

No competing financial interests exist.

### References

- Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. *Science* 284:143–147.
- Baksh D, R Yao and RS Tuan. (2007). Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. *Stem Cells* 25:1384–1392.
- Jones EA, A Crawford, A English, K Henshaw, J Mundy, D Corscadden, T Chapman, P Emery, P Hatton and D McGonagle. (2008). Synovial fluid mesenchymal stem cells in health and early osteoarthritis: detection and functional evaluation at the single-cell level. *Arthritis Rheum* 58:1731–1740.
- Koelling S, J Kruegel, M Irmer, JR Path, B Sadowski, X Miro and N Miosge. (2009). Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis. *Cell Stem Cell* 4:324–335.
- Farre-Guasch E, C Marti-Page, F Hernandez-Alfaro, J Klein-Nulend and N Casals. (2010). Buccal fat pad, an oral access source of human adipose stem cells with potential for osteochondral tissue engineering: an in vitro study. *Tissue Eng Part C Methods* 16:1083–1094.
- Tallone T, C Realini, A Bohmler, C Kornfeld, G Vassalli, T Moccetti, S Bardelli and G Soldati. (2011). Adult human adipose tissue contains several types of multipotent cells. *J Cardiovasc Transl Res* 4:200–210.
- Leijten JC, N Georgi, L Wu, CA van Blitterswijk and M Karperien. (2013). Cell sources for articular cartilage repair strategies: shifting from monocultures to cocultures. *Tissue Eng Part B Rev* 19:31–40.
- Estes BT, BO Diekman, JM Gimble and F Guilak. (2010). Isolation of adipose-derived stem cells and their induction to a chondrogenic phenotype. *Nat Protoc* 5:1294–1311.
- Siddappa R, R Licht, C van Blitterswijk and J de Boer. (2007). Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. *J Orthop Res* 25:1029–1041.
- Phinney DG, G Kopen, W Righter, S Webster, N Tremain and DJ Prockop. (1999). Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. *J Cell Biochem* 75:424–436.
- Tokalov SV, S Gruener, S Schindler, AS Iagunov, M Baumann and ND Abolmaali. (2007). A number of bone marrow mesenchymal stem cells but neither phenotype nor differentiation capacities changes with age of rats. *Mol Cells* 24:255–260.
- Tokalov SV, S Gruener, S Schindler, G Wolf, M Baumann and N Abolmaali. (2007). Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats. *Stem Cells Dev* 16:439–446.
- Gallay SH, Y Miura, CN Commisso, JS Fitzsimmons and SW O'Driscoll. (1994). Relationship of donor site to chondrogenic potential of periosteum in vitro. *J Orthop Res* 12:515–525.
- De Bari C, F Dell'Accio and FP Luyten. (2001). Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. *Arthritis Rheum* 44:85–95.
- Vacanti V, E Kong, G Suzuki, K Sato, JM Canty and T Lee. (2005). Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. *J Cell Physiol* 205:194–201.
- Tan Q, PPY Lui and YF Rui. (2012). Effect of in vitro passaging on the stem cell-related properties of tendon-derived stem cells—implications in tissue engineering. *Stem Cells Dev* 21:790–800.
- Jansen BJ, C Gilissen, H Roelofs, A Schaap-Oziemlak, JA Veltman, RA Raymakers, JH Jansen, G Kogler, CG Figdor, R Torensma and GJ Adema. (2010). Functional differences between mesenchymal stem cell populations are reflected by their transcriptome. *Stem Cells Dev* 19:481–490.
- Zou Z, Y Zhang, L Hao, F Wang, D Liu, Y Su and H Sun. (2010). More insight into mesenchymal stem cells and their effects inside the body. *Expert Opin Biol Ther* 10:215–230.
- Tome M, P Lopez-Romero, C Albo, JC Sepulveda, B Fernandez-Gutierrez, A Dopazo, A Bernad and MA Gonzalez. (2011). miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. *Cell Death Differ* 18:985–995.
- Nie Y, BM Han, XB Liu, JJ Yang, F Wang, XF Cong and X Chen. (2011). Identification of microRNAs involved in hypoxia- and serum deprivation-induced apoptosis in mesenchymal stem cells. *Int J Biol Sci* 7:762–768.
- Laine SK, JJ Alm, SP Virtanen, HT Aro and TK Laitala-Leinonen. (2012). MicroRNAs miR-96, miR-124, and miR-199a regulate gene expression in human bone marrow-

- derived mesenchymal stem cells. *J Cell Biochem* 113:2687–2695.
22. Mentink A, M Hulsman, N Groen, R Licht, KJ Dechering, J van der Stok, HA Alves, WJ Dhert, EP van Someren, et al. (2013). Predicting the therapeutic efficacy of MSC in bone tissue engineering using the molecular marker CADM1. *Biomaterials* 34:4592–4601.
  23. Portalska KJ, N Groen, G Krenning, N Georgi, A Mentink, MC Harmsen, C van Blitterswijk and J de Boer. (2013). The effect of donor variation and senescence on endothelial differentiation of human mesenchymal stromal cells. *Tissue Eng Part A* 19:2318–2329.
  24. Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, D Prockop and E Horwitz. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 8:315–317.
  25. Both SK, AJ van der Muijsenbergh, CA van Blitterswijk, J de Boer and JD de Bruijn. (2007). A rapid and efficient method for expansion of human mesenchymal stem cells. *Tissue Eng* 13:3–9.
  26. Wu L, JC Leijten, N Georgi, JN Post, CA van Blitterswijk and M Karperien. (2011). Trophic effects of mesenchymal stem cells increase chondrocyte proliferation and matrix formation. *Tissue Eng Part A* 17:1425–1436.
  27. Wettenhall JM and GK Smyth. (2004). limmaGUI: a graphical user interface for linear modeling of microarray data. *Bioinformatics* 20:3705–3706.
  28. Szklarczyk D, A Franceschini, M Kuhn, M Simonovic, A Roth, P Minguéz, T Doerks, M Stark, J Muller, et al. (2011). The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. *Nucleic Acids Res* 39:D561–D568.
  29. Jensen LJ, M Kuhn, M Stark, S Chaffron, C Creevey, J Muller, T Doerks, P Julien, A Roth, et al. (2009). STRING 8—a global view on proteins and their functional interactions in 630 organisms. *Nucleic Acids Res* 37:D412–D416.
  30. Hassan MQ, Y Maeda, H Taipaleenmaki, W Zhang, M Jafferji, JA Gordon, Z Li, CM Croce, AJ van Wijnen, et al. (2012). miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. *J Biol Chem* 287:42084–42092.
  31. Shen M, T Kawamoto, W Yan, K Nakamasu, M Tamagami, Y Koyano, M Noshiro and Y Kato. (1997). Molecular characterization of the novel basic helix-loop-helix protein DEC1 expressed in differentiated human embryo chondrocytes. *Biochem Biophys Res Commun* 236:294–298.
  32. Muller R and EF Wagner. (1984). Differentiation of F9 teratocarcinoma stem cells after transfer of c-fos proto-oncogenes. *Nature* 311:438–442.
  33. Bartmann C, E Rohde, K Schallmoser, P Purstner, G Lanzer, W Linkesch and D Strunk. (2007). Two steps to functional mesenchymal stromal cells for clinical application. *Transfusion* 47:1426–1435.
  34. Phinney DG, G Kopen, W Righter, S Webster, N Tremain and DJ Prockop. (1999). Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. *J Cell Biochem* 75:424–436.
  35. Van Beveren C, RL Mitchell, C Henning-Chubb, E Huberman and IM Verma. (1987). Expression of the c-fos gene during differentiation. *Adv Exp Med Biol* 213:263–274.
  36. Ijiri K, LF Zerbini, H Peng, RG Correa, B Lu, N Walsh, Y Zhao, N Taniguchi, XL Huang, et al. (2005). A novel role for GADD45beta as a mediator of MMP-13 gene expression during chondrocyte terminal differentiation. *J Biol Chem* 280:38544–38555.
  37. Loveridge N, C Farquharson, JE Hesketh, SB Jakowlew, CC Whitehead and BH Thorp. (1993). The control of chondrocyte differentiation during endochondral bone growth in vivo: changes in TGF-beta and the proto-oncogene c-myc. *J Cell Sci* 105 (Pt 4):949–956.
  38. Solorio LD, AS Fu, R Hernandez-Irizarry and E Alsberg. (2010). Chondrogenic differentiation of human mesenchymal stem cell aggregates via controlled release of TGF-beta1 from incorporated polymer microspheres. *J Biomed Mater Res A* 92:1139–1144.
  39. Zhang Y, XH Feng and R Derynck. (1998). Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. *Nature* 394:909–913.
  40. Tuddenham L, G Wheeler, S Ntounia-Fousara, J Waters, MK Hajihosseini, I Clark and T Dalmay. (2006). The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. *FEBS Lett* 580:4214–4217.
  41. Tardif G, D Hum, JP Pelletier, N Duval and J Martel-Pelletier. (2009). Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. *BMC Musculoskelet Disord* 10:148.
  42. Nicolas FE, H Pais, F Schwach, M Lindow, S Kauppinen, V Moulton and T Dalmay. (2011). mRNA expression profiling reveals conserved and non-conserved miR-140 targets. *RNA Biol* 8:607–615.
  43. Bakhshandeh B, M Soleimani, SH Paylakhi and N Ghaemi. (2012). A microRNA signature associated with chondrogenic lineage commitment. *J Genet* 91:171–182.
  44. Jin EJ, JH Park, SY Lee, JS Chun, OS Bang and SS Kang. (2006). Wnt-5a is involved in TGF-beta3-stimulated chondrogenic differentiation of chick wing bud mesenchymal cells. *Int J Biochem Cell Biol* 38:183–195.
  45. Papachristou DJ, P Pirttiniemi, T Kantomaa, AG Papatassiliou and EK Basdra. (2005). JNK/ERK-AP-1/Runx2 induction “paves the way” to cartilage load-ignited chondroblastic differentiation. *Histochem Cell Biol* 124:215–223.
  46. Abouheif MM, T Nakasa, H Shibuya, T Niimoto, W Kongcharoensombat and M Ochi. (2010). Silencing microRNA-34a inhibits chondrocyte apoptosis in a rat osteoarthritis model in vitro. *Rheumatology* 49:2054–2060.
  47. He L, X He, LP Lim, E de Stanchina, Z Xuan, Y Liang, W Xue, L Zender, J Magnus, et al. (2007). A microRNA component of the p53 tumour suppressor network. *Nature* 447:1130–1134.
  48. Wu T, H Zhou, Y Hong, J Li, X Jiang and H Huang. (2012). miR-30 family members negatively regulate osteoblast differentiation. *J Biol Chem* 287:7503–7511.
  49. Kim D, J Song and EJ Jin. (2010). MicroRNA-221 regulates chondrogenic differentiation through promoting proteosomal degradation of slug by targeting Mdm2. *J Biol Chem* 285:26900–26907.
  50. Karlsen TA, A Shahdadfar and JE Brinckmann. (2011). Human primary articular chondrocytes, chondroblasts-like cells, and dedifferentiated chondrocytes: differences in gene, microRNA, and protein expression and phenotype. *Tissue Eng Part C Methods* 17:219–227.
  51. Rogler CE, L Levoci, T Ader, A Massimi, T Tchakovskaya, R Norel and LE Rogler. (2009). MicroRNA-23b cluster microRNAs regulate transforming growth factor-

- beta/bone morphogenetic protein signaling and liver stem cell differentiation by targeting Smads. *Hepatology* 50: 575–584.
52. Goldring MB and KB Marcu. (2012). Epigenomic and microRNA-mediated regulation in cartilage development, homeostasis, and osteoarthritis. *Trends Mol Med* 18:109–118.
53. Sun D, J Zhang, J Xie, W Wei, M Chen and X Zhao. (2012). MiR-26 controls LXR-dependent cholesterol efflux by targeting ABCA1 and ARL7. *FEBS Lett* 586:1472–1479.
54. Kulshreshtha R, M Ferracin, SE Wojcik, R Garzon, H Alder, FJ Agosto-Perez, R Davuluri, CG Liu, CM Croce, et al. (2007). A microRNA signature of hypoxia. *Mol Cell Biol* 27:1859–1867.
55. Sorrentino A, M Ferracin, G Castelli, M Biffoni, G Tomaselli, M Baiocchi, A Fatica, M Negrini, C Peschle and M Valtieri. (2008). Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. *Exp Hematol* 36:1035–1046.
56. Yang B, H Guo, Y Zhang, L Chen, D Ying and S Dong. (2011). MicroRNA-145 regulates chondrogenic differentiation of mesenchymal stem cells by targeting Sox9. *PLoS One* 6:e21679.
57. Koh W, CT Sheng, B Tan, QY Lee, V Kuznetsov, LS Kiang and V Tanavde. (2010). Analysis of deep sequencing microRNA expression profile from human embryonic stem cells derived mesenchymal stem cells reveals possible role of let-7 microRNA family in downstream targeting of hepatic nuclear factor 4 alpha. *BMC Genomics* 11 Suppl 1:S6.

Address correspondence to:

*Marcel Karperien, PhD*  
*Department of Developmental BioEngineering*  
*Faculty of Science and Technology*  
*MIRA Institute for Biomedical Technology*  
*and Technical Medicine*  
*University of Twente*  
*P.O. Box 217*  
*Enschede 7500AE*  
*The Netherlands*

*E-mail: h.b.j.karperien@utwente.nl*

Received for publication November 13, 2014

Accepted after revision April 24, 2015

Prepublished on Liebert Instant Online April 27, 2015